Cited by 710Cancer-related Molecular PathwaysHeat shock proteins researchCell death mechanisms and regulation

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy

Tovar, Christian, Rosinski, James, Filipovic, Zoran, Higgins, Brian, Kolinsky, Kenneth, Hilton, Holly, Zhao, Xiaolan, Vu, Binh T., Qing, Weiguo, Packman, Kathryn, Myklebost, Ola, Heimbrook, David C., Vassilev, Lyubomir T.·2006·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.0507493103

Open this paper in CoChat — free account

Abstract

The p53 tumor suppressor retains its wild-type conformation and transcriptional activity in half of all human tumors, and its activation may offer a therapeutic benefit. However, p53 function could be compromised by defective signaling in the p53 pathway. Using a small-molecule MDM2 antagonist, nutlin-3, to probe downstream p53 signaling we find that the cell-cycle arrest function of the p53 pathway is preserved in multiple tumor-derived cell lines expressing wild-type p53, but many have a reduced ability to undergo p53-dependent apoptosis. Gene array analysis revealed attenuated expression of multiple apoptosis-related genes. Cancer cells with mdm2 gene amplification were most sensitive to nutlin-3 in vitro and in vivo , suggesting that MDM2 overexpression may be the only abnormality in the p53 pathway of these cells. Nutlin-3 also showed good efficacy against tumors with normal MDM2 expression, suggesting that many of the patients with wild-type p53 tumors may benefit from antagonists of the p53–MDM2 interaction.

Integrity signals

Registry

Crossref · 10.1073/pnas.0507493103

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Surfing the p53 network
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Self-citation
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,691
Live or let die: the cell's response to p53
Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967

Show all 36 references

Research works printed but not linked: 4

K. H. Vousden, C. Prives Cell 120, 7–10 (2005).
D. P. Steensma, M. Timm, T. E. Witzig Methods Mol. Med 85, 323–332 (2003).
K. Satyamoorthy, N. H. Chehab, M. J. Waterman, M. C. Lien, W. S. El-Deiry, M. Herlyn, T. D. Halazonetis Cell Growth Differ 11, 467–474 (2000).
H. Yang, Z. Filipovic, D. Brown, S. N. Breit, L. T. Vassilev Mol. Cancer Ther 2, 1023–1029 (2003).

Sorted by citations

Items 201–300 of 710

A genome‐wide si RNA screen for regulators of tumor suppressor p53 activity in human non‐small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment
Olst, E. S., Blijlevens, M., de Menezes, R. X., van der Meulen‐Muileman, I. H., Smit, E. F., & van Beusechem, V. W. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12052 · Cited by 65
Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21)
Drakos, E., Singh, R. R., Rassidakis, G. Z., Schlette, E. J., Li, J., Claret, F. X., Ford, R. J., Vega, F., & Medeiros, L. J. (2011) · Leukemia · doi:10.1038/leu.2011.28 · Cited by 67
The Numb/p53 circuitry couples replicative self-renewal and tumor suppression in mammary epithelial cells
Tosoni, D., Zecchini, S., Coazzoli, M., Colaluca, I. N., Mazzarol, G., Rubio, A., Caccia, M., Villa, C. E., Zilian, O., Fiore, P. P. D., et al. (2015) · The Journal of Cell Biology · doi:10.1083/jcb.201505037 · Cited by 68
At a Crossroads to Cancer: How p53-Induced Cell Fate Decisions Secure Genome Integrity
Rizzotto, D., Englmaier, L., & Villunger, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910883 · Cited by 69
Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
Hároníková, L., Bonczek, O., Zatloukalová, P., Kokas, F. Z., Kucerikova, M., Coates, P. J., Fåhræus, R., & Vojtěšek, B. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00293-6 · Cited by 72
Heat shock factor-1 modulates p53 activity in the transcriptional response to DNA damage
Logan, I. R., McNeill, H. V., Cook, S., Lü, X., Meek, D. W., Fuller-Pace, F. V., Lunec, J., & Robson, C. N. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp180 · Cited by 68
MDM2 inhibition rescues neurogenic and cognitive deficits in a mouse model of fragile X syndrome
Li, Y., Stockton, M. E., Bhuiyan, I., Eisinger, B. E., Gao, Y., Miller, J. L., Bhattacharyya, A., & Zhao, X. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9370 · Cited by 66
Self-citation
Updates on p53: modulation of p53 degradation as a therapeutic approach
Dey, A., Verma, C. S., & Lane, D. P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604098 · Cited by 65
MDM2-Dependent Inhibition of p53 Is Required for Epstein-Barr Virus B-Cell Growth Transformation and Infected-Cell Survival
Forte, E., & Luftig, M. A. (2009) · Journal of Virology · doi:10.1128/jvi.01681-08 · Cited by 65
Tumor suppressor p53 promotes ferroptosis in oxidative stress conditions independent of modulation of ferroptosis by p21, CDKs, RB, and E2F
Kuganesan, N., Dlamini, S., Tillekeratne, L. M. V., & Taylor, W. R. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101365 · Cited by 71
Wild type p53 reactivation: From lab bench to clinic
Selivanova, G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.03.049 · Cited by 68
A Genetic Screen Identifies TCF3/E2A and TRIAP1 as Pathway-Specific Regulators of the Cellular Response to p53 Activation
Andrysík, Z., Kim, J., Tan, A. C., & Espinosa, J. M. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.014 · Cited by 68
MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway
Huang, K., Tang, Y., He, L., & Dai, Y. (2015) · Oncology Reports · doi:10.3892/or.2015.4458 · Cited by 65
Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
VOON, Y.-L., Wong, P., & Khoo, A. S. B. (2017) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557517666170717125821 · Cited by 66
The p53-MDM2 network: from oscillations to apoptosis
Bose, I., & Ghosh, B. (2007) · Journal of Biosciences · doi:10.1007/s12038-007-0103-3 · Cited by 65
p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation
Xia, M., Knezevic, D., & Vassilev, L. T. (2011) · Oncogene · doi:10.1038/onc.2010.413 · Cited by 64
Self-citation
p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors
Li, B., Cheng, Q., Li, Z., & Chen, J. (2010) · Cell Cycle · doi:10.4161/cc.9.7.11255 · Cited by 64
Small molecule compounds targeting the p53 pathway: are we finally making progress?
Yu, X., Narayanan, S., Vázquez, A., & Carpizo, D. R. (2014) · APOPTOSIS · doi:10.1007/s10495-014-0990-3 · Cited by 68
Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program
Carol, H., Reynolds, C. P., Kang, M. H., Keir, S. T., Maris, J. M., Gorlick, R. G., Kolb, E. A., Billups, C. A., Geier, B., Kurmasheva, R. T., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24235 · Cited by 64
Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
Higgins, B., Glenn, K., Walz, A., Tovar, C., Filipovic, Z., Hussain, S., Lee, E., Kolinsky, K., Tannu, S., Adames, V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0460 · Cited by 63
Self-citation
Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway
Bornhauser, B. C., Bonapace, L., Lindholm, D., Maza, R. M., Cario, G., Schrappe, M., Niggli, F. K., Schäfer, B. W., & Bourquin, J. (2007) · Blood · doi:10.1182/blood-2006-12-060970 · Cited by 63
Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation
París, R., Henry, R. E., Stephens, S. J., McBryde, M., & Espinosa, J. M. (2008) · Cell Cycle · doi:10.4161/cc.6420 · Cited by 62
RING Finger E3 Ubiquitin Ligases: Structure and Drug Discovery
Chasapis, C. T., & Spyroulias, G. A. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789271825 · Cited by 65
Of dogs and men: Comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma
Rankin, K. S., Starkey, M., Lunec, J., Gerrand, C., Murphy, S., & Biswas, S. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23341 · Cited by 62
RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38
Weilbacher, A., Gutekunst, M., Oren, M., Aulitzky, W. E., & van der Kuip, H. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.284 · Cited by 62
Tumor cell survival dependence on the DHX9 DExH-box helicase
Lee, T., Paquet, M., Larsson, O. S., & Pelletier, J. (2016) · Oncogene · doi:10.1038/onc.2016.52 · Cited by 61
Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma
Saha, M. N., Jiang, H., & Chang, H. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.6.12535 · Cited by 60
Enantioselective construction of imidazolines having vicinal tetra-substituted stereocenters by direct Mannich reaction of α-substituted α-isocyanoacetates with ketimines
Nakamura, S., Yamaji, R., & Iwanaga, M. (2016) · Chemical Communications · doi:10.1039/c6cc02911f · Cited by 60
MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells
Wang, B., Fang, L., Zhao, H., Xiang, T., & Wang, D. (2012) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms053 · Cited by 58
Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53
Miyamoto, T., Lo, P. H. Y., Saichi, N., Ueda, K., Hirata, M., Tanikawa, C., & Matsuda, K. (2017) · Science Advances · doi:10.1126/sciadv.1603204 · Cited by 60
Direct and Propagated Effects of Small Molecules on Protein–Protein Interaction Networks
Cesa, L. C., Mapp, A. K., & Gestwicki, J. E. (2015) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2015.00119 · Cited by 63
Intrinsic checkpoint deficiency during cell cycle re-entry from quiescence
Matson, J. P., House, A. M., Grant, G. D., Wu, H., Perez, J., & Cook, J. G. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201902143 · Cited by 59
Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
DeVine, T., & Dai, M. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319180009 · Cited by 58
Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival
Mullany, L. K., Wong, K., Marciano, D. C., Katsonis, P., King, E. R., Ren, Y. A., Lichtarge, O., & Richards, J. S. (2015) · Neoplasia · doi:10.1016/j.neo.2015.10.003 · Cited by 59
The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p
Towers, C. G., Guarnieri, A. L., Micalizzi, D. S., Harrell, J. C., Gillen, A. E., Kim, J., Wang, C.-A., Oliphant, M. U. J., Drasin, D. J., Guney, M. A., et al. (2015) · Nature Communications · doi:10.1038/ncomms10077 · Cited by 57
Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models
Moro, M., Paolo, D. D., Milione, M., Centonze, G., Bornaghi, V., Borzi, C., Gandellini, P., Perri, P., Pastorino, U., Ponzoni, M., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.07.006 · Cited by 57
Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors
Vaseva, A. V., Yallowitz, A. R., Marchenko, N. D., Xu, S., & Moll, U. M. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.39 · Cited by 55
Discovery of a new small-molecule inhibitor of p53–MDM2 interaction using a yeast-based approach
Leão, M., Pereira, C., Bisio, A., Ciribilli, Y., Paiva, A. M. O., Machado, N., Palmeira, A., Fernandes, M. X., Sousa, E., Pinto, M. M. M., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.01.032 · Cited by 56
MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
Saiki, A. Y., Caenepeel, S., Yu, D., Lofgren, J. A., Osgood, T., Robertson, R., Canon, J., Su, C., Jones, A., Zhao, X., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1918 · Cited by 55
Self-citation
MDM2 Gene Amplification Is Correlated to Tumor Progression but not to the Presence of SNP309 or TP53 Mutational Status in Primary Colorectal Cancers
Forslund, A., Zeng, Z., Qin, L.-X., Rosenberg, S., Ndubuisi, M., Pincas, H., Gerald, W., Notterman, D. A., Barany, F., & Paty, P. B. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0239 · Cited by 54
Genotoxic Stress–Induced Expression of p53 and Apoptosis in Leukemic Clam Hemocytes with Cytoplasmically Sequestered p53
Böttger, S. A., Jerszyk, E., Low, B., & Walker, C. W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-06-0968 · Cited by 53
Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones
Ren, Y. A., Mullany, L. K., Liu, Z., Herron, A. J., Wong, K., & Richards, J. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1046 · Cited by 53
Role of Deubiquitinases in Human Cancers: Potential Targeted Therapy
Lai, K. P., Chen, J., & Tse, W. K. F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072548 · Cited by 52
Stabilization of Protein–Protein Interactions in chemical biology and drug discovery
Bier, D., Thiel, P., Briels, J. M., & Ottmann, C. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.05.002 · Cited by 56
MicroRNA-16 mediates the regulation of a senescence–apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas
Kitadate, A., Ikeda, S., Teshima, K., Ito, M., Toyota, I., Hasunuma, N., Takahashi, N., Miyagaki, T., Sugaya, M., & Tagawa, H. (2015) · Oncogene · doi:10.1038/onc.2015.435 · Cited by 53
Estrogen Receptor-β Modulation of the ERα-p53 Loop Regulating Gene Expression, Proliferation, and Apoptosis in Breast Cancer
Lu, W., & Katzenellenbogen, B. S. (2017) · Hormones and Cancer · doi:10.1007/s12672-017-0298-1 · Cited by 55
Role of Mdm4 in drug sensitivity of breast cancer cells
Lam, S., Lodder, K., Teunisse, A. F. A. S., Rabelink, M. J. W. E., Schutte, M., & Jochemsen, A. G. (2010) · Oncogene · doi:10.1038/onc.2009.522 · Cited by 52
Binding cavities and druggability of intrinsically disordered proteins
Zhang, Y., Cao, H., & Liu, Z. (2015) · Protein Science · doi:10.1002/pro.2641 · Cited by 51
Pharmacological activation of the p53 pathway in haematological malignancies
Saha, M. N., Micallef, J., Qiu, L., & Chang, H. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2009.070961 · Cited by 51
Activation of Erk and p53 regulates copper oxide nanoparticle-induced cytotoxicity in keratinocytes and fibroblasts
Luo, C. Y., Li, Y., Yang, L., Long, J., Zheng, Y., Liu, J., Xiao, S., & Jia, J. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s67688 · Cited by 51
Regulation of MDM2 Stability After DNA Damage
Li, J., & Kurokawa, M. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.24994 · Cited by 49
Targeting the MDM2/MDM4 Interaction Interface as a Promising Approach for p53 Reactivation Therapy
Pellegrino, M., Mancini, F., Lucà, R., Coletti, A., Giacchè, N., Manni, I., Arisi, I., Florenzano, F., Teveroni, E., Buttarelli, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0439 · Cited by 49
Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas
Künkele, A., Preter, K. D., Heukamp, L. C., Thor, T., Pajtler, K. W., Hartmann, W., Mittelbronn, M. G. A., Grotzer, M. A., Deubzer, H. E., Speleman, F., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos115 · Cited by 49
Nutlins and Ionizing Radiation in Cancer Therapy
Impicciatore, G. G., Sancilio, S., Miscia, S., & Pietro, R. D. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791033932 · Cited by 50
Therapeutic Targets in the ARF Tumor Suppressor Pathway
Saporita, A. J., Maggi, L. B., Apicelli, A. J., & Weber, J. D. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707781058869 · Cited by 49
Systems biology analysis reveals role of MDM2 in diabetic nephropathy
Saito, R., Arjó, A. R., You, Y.-H., Darshi, M., Espen, B. V., Miyamoto, S., Pham, J., Pu, M., Romoli, S., Natarajan, L., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87877 · Cited by 49
Analysis of the MDM2 antagonist nutlin‐3 in human prostate cancer cells
Logan, I. R., McNeill, H. V., Cook, S., Lü, X., Lunec, J., & Robson, C. N. (2007) · The Prostate · doi:10.1002/pros.20568 · Cited by 49
BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death
Wade, M., Rodewald, L. W., Espinosa, J. M., & Wahl, G. M. (2008) · Cell Cycle · doi:10.4161/cc.7.13.6072 · Cited by 48
HIPK2 Regulation by MDM2 Determines Tumor Cell Response to the p53-Reactivating Drugs Nutlin-3 and RITA
Rinaldo, C., Prodosmo, A., Siepi, F., Moncada, A., Sacchi, A., Selivanova, G., & Soddu, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0337 · Cited by 48
p53-Induced Apoptosis Occurs in the Absence of p14ARF in Malignant Pleural Mesothelioma
Hopkins-Donaldson, S., Belyanskaya, A. L., Simões‐Wüst, A. P., Sigrist, B., Kurtz, S., Zangemeister‐Wittke, U., & Stahel, R. A. (2006) · Neoplasia · doi:10.1593/neo.06148 · Cited by 47
The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients
Kelleher, M., Fruhwirth, G. O., Patel, G. S., Ofo, E., Festy, F., Barber, P. R., Ameer‐Beg, S., Vojnovic, B., Gillett, C., Coolen, A. C. C., et al. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0116-y · Cited by 48
Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation
Pan, D., Pan, L.-Z., Hill, R., Marcato, P., Shmulevitz, M., Vassilev, L. T., & Lee, P. W. K. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.325 · Cited by 48
Self-citation
Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer
Maerken, T. V., Rihani, A., Goethem, A. V., Paepe, A. D., Speleman, F., & Vandesompele, J. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.11.002 · Cited by 47
Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule
Soares, J., Raimundo, L., Pereira, N. A. L., Monteiro, Â., Gomes, S., Bessa, C., Pereira, C., Queiróz, G., Bisio, A., Fernandes, J. C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6775 · Cited by 47
Nutlin-3a Enhances Natural Killer Cell–Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors
Veneziani, I., Infante, P., Ferretti, E., Melaiu, O., Battistelli, C., Lucarini, V., Compagnone, M., Nicoletti, C., Castellano, A., Petrini, S., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0313 · Cited by 48
Helping the released guardian: Drug combinations for supporting the anticancer activity of HDM2 (MDM2) antagonists
Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L. (2019) · Cancers · doi:10.3390/cancers11071014 · Cited by 46
MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro
Wang, J., Zheng, T., Chen, X., Song, X., Meng, X., Bhatta, N., Pan, S., Jiang, H., & Liu, L. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06440.x · Cited by 45
Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond
Choi, J., Bogenberger, J. M., & Tibes, R. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00711-3 · Cited by 45
A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer
Miller, J. J., Gaiddon, C., & Storr, T. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00163e · Cited by 47
Molecular target therapies in endometrial cancer: From the basic research to the clinic
Gadducci, A., Tana, R., Cosio, S., FANUCCHI, A., & Genazzani, A. R. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801953556 · Cited by 46
Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells
Rigatti, M. J., Verma, R., Belinsky, G. S., Rosenberg, D. W., & Giardina, C. A. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20795 · Cited by 45
Targeting the p53 Pathway
Golubovskaya, V., & Cance, W. G. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.06.003 · Cited by 45
Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells
Zhang, X., Cheng, L., Minn, K. T., Madan, R., Godwin, A. K., Shridhar, V., & CHIEN, J. R. (2014) · Oncotarget · doi:10.18632/oncotarget.2497 · Cited by 45
Quantification of HER family receptors in breast cancer
Nuciforo, P. G., Radosevic‐Robin, N., Ng, T., & Scaltriti, M. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0561-8 · Cited by 49
A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)
Skalniak, Ł., Surmiak, E., & Holak, T. A. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1582645 · Cited by 45
Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities
Kumari, S., Sharma, V., Tiwari, R., Maurya, J. P., Subudhi, B. B., & Senapati, D. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174807 · Cited by 47
Hepatic MDM2 Causes Metabolic Associated Fatty Liver Disease by Blocking Triglyceride‐VLDL Secretion via ApoB Degradation
Lin, H., Wang, L., Liu, Z., Long, K., Kong, M., Ye, D., Chen, X., Wang, K., Wu, K. K., Fan, M., et al. (2022) · Advanced Science · doi:10.1002/advs.202200742 · Cited by 43
The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53
Drakos, E., Atsaves, V., Schlette, E. J., Li, J.-D., Papanastasi, E., Rassidakis, G. Z., & Medeiros, L. J. (2009) · Leukemia · doi:10.1038/leu.2009.180 · Cited by 44
Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL
Meijer, A., Kruyt, F. A. E., van der Zee, A. G. J., Hollema, H., Le, P., ten Hoor, K. A., Groothuis, G. M. M., Quax, W. J., de Vries, E. G. E., & de Jong, S. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.636 · Cited by 44
Variability in functional p53 reactivation by PRIMA-1Met/APR-246 in Ewing sarcoma
Aryee, D. N. T., Niedan, S., Bán, J., Schwentner, R., Muehlbacher, K., Kauer, M. O., Kofler, R., & Kovar, H. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.635 · Cited by 45
Toward understanding ubiquitin-modifying enzymes: from pharmacological targeting to proteomics
Lill, J. R., & Wertz, I. E. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.01.005 · Cited by 47
The impact of post-transcriptional regulation in the p53 network
Freeman, J. A., & Espinosa, J. M. (2012) · Briefings in Functional Genomics · doi:10.1093/bfgp/els058 · Cited by 46
Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells
Janz, M., Stühmer, T., Vassilev, L. T., & Bargou, R. C. (2007) · Leukemia · doi:10.1038/sj.leu.2404565 · Cited by 45
Self-citation
A Cyclized Helix‐Loop‐Helix Peptide as a Molecular Scaffold for the Design of Inhibitors of Intracellular Protein–Protein Interactions by Epitope and Arginine Grafting
Fujiwara, D., Kitada, H., Oguri, M., Nishihara, T., Michigami, M., Shiraishi, K., Yuba, E., Nakase, I., Im, H., Cho, S., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201603230 · Cited by 45
Anticancer effects of the p53 activator nutlin-3 in Ewing’s sarcoma cells
Sonnemann, J., Palani, C. D., Wittig, S., Becker, S., Eichhorn, F., Voigt, A., & Beck, J. F. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.01.015 · Cited by 43
Differential Effects of Procaspase-3 Activating Compounds in the Induction of Cancer Cell Death
West-Szymanski, D. C., Qin, Y., Peterson, Q. P., Thomas, D., Palchaudhuri, R., Morrison, K. C., Lucas, P. W., Palmer, A. E., Fan, T. M., & Hergenrother, P. J. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200673n · Cited by 43
p53-based therapeutics for head and neck squamous cell carcinoma
Tassone, P. T., Old, M. O., Teknos, T. N., & Pan, Q. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.03.447 · Cited by 43
Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non–Small Cell Lung Cancer Xenograft Models
Hai, J., Sakashita, S., Allo, G., Ludkovski, O., Ng, C., Shepherd, F. A., & Tsao, M. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000584 · Cited by 44
Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway
Kurosu, T., Wu, N., Oshikawa, G., Kagechika, H., & Miura, O. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0457-0 · Cited by 43
Persistent p21 Expression after Nutlin-3a Removal Is Associated with Senescence-like Arrest in 4N Cells
Shen, H., & Maki, C. G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.124990 · Cited by 43
Structural and Functional Comparison of the RING Domains of Two p53 E3 Ligases, Mdm2 and Pirh2
Shloush, J., Vlassov, J. E., Engson, I., Duan, S., Saridakis, V., Dhe-paganon, S., Raught, B., Sheng, Y., & Arrowsmith, C. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.157669 · Cited by 42
Targeted therapies for bone sarcomas
Heymann, D., & Rédiní, F. (2013) · BoneKEy Reports · doi:10.1038/bonekey.2013.112 · Cited by 42
Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma
Ohnstad, H. O., Castro, R., Sun, J., Heintz, K., Vassilev, L. T., Bjerkehagen, B., Kresse, S. H., Meza‐Zepeda, L. A., & Myklebost, O. (2012) · Cancer · doi:10.1002/cncr.27837 · Cited by 42
Self-citation
Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells
Hori, T., Kondo, T., Kanamori, M., Tabuchi, Y., Ogawa, R., Zhao, Q., Ahmed, K., Yasuda, T., Seki, S., Suzuki, K., et al. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.06.002 · Cited by 42
MYCN Sensitizes Human Neuroblastoma to Apoptosis by HIPK2 Activation through a DNA Damage Response
Petroni, M., Veschi, V., Prodosmo, A., Rinaldo, C., Massimi, I., Carbonari, M., Dominici, C., McDowell, H. P., Rinaldi, C., Screpanti, I., et al. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0227 · Cited by 42
Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity
VOON, Y.-L., Ahmad, M., Wong, P., Husaini, R., Ng, W., Leong, C., Lane, D. P., & Khoo, A. S. B. (2015) · Oncology Reports · doi:10.3892/or.2015.4177 · Cited by 42
Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells
Valente, L. J., Aubrey, B. J., Herold, M. J., Kelly, G. L., Happo, L., Scott, C. L., Newbold, A., Johnstone, R. W., Huang, D. C. S., Vassilev, L. T., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.059 · Cited by 40
Self-citation
The Role of MDM2 in Promoting Genome Stability versus Instability
Saadatzadeh, M. R., Elmi, A. N., Pandya, P. H., Bijangi‐Vishehsaraei, K., Ding, J., Stamatkin, C. W., Cohen‐Gadol, A., & Pollok, K. E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102216 · Cited by 44
Dissection of mechanisms of Chinese medicinal formula Si-Miao-Yong-an decoction protects against cardiac hypertrophy and fibrosis in isoprenaline-induced heart failure
Zhao, Y., Jiang, Y., Chen, Y., Zhang, F., Zhang, X., Zhu, L., & Yao, X. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112050 · Cited by 41
Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase
Rana, S., Mallareddy, J. R., Singh, S., Boghean, L., & Natarajan, A. (2021) · Cancers · doi:10.3390/cancers13215506 · Cited by 43

Authors: Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., Myklebost, O., Heimbrook, D. C., & Vassilev, L. T.
Affiliations: *Roche Research Center, Hoffmann-La Roche Inc., Nutley, NJ 07110; and
F. Hoffmann-La Roche AG (CH)
Institute for Cancer Research, Norwegian Radium Hospital, 0310 Oslo, Norway
ORCID: Higgins, Brian
Zhao, Xiaolan
Vu, Binh T.
Packman, Kathryn
Myklebost, Ola
Vassilev, Lyubomir T.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2006-01-27
Volume: 103
Issue: 6
Pages: 1888-1893
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.0507493103
OpenAlex: W1993263392
Cited by: 708
References: 36
Citations by year: 2026: 17 · 2025: 24 · 2024: 15 · 2023: 39 · 2022: 23 · 2021: 27 · 2020: 25 · 2019: 33 · 2018: 20 · 2017: 27 · 2016: 44 · 2015: 39 · 2014: 45 · 2013: 39 · 2012: 47
FWCI: 25.66
Type: journal article
Language: en
Open access: closed
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords: MDM2 inhibitors, Nutlin-3, p53 pathway, p53-dependent apoptosis, cell cycle arrest, MDM2 amplification, p53-MDM2 interaction, apoptosis-related gene expression, cancer therapy
MeSH terms: Animals, Antineoplastic Agents, Cell Cycle, Cell Line, Humans, Imidazoles, Mice, Nude, Neoplasms, Piperazines, Signal Transduction, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Gene Expression Profiling, Xenograft Model Antitumor Assays, Mice, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks